

Matteo Simonelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4915859/publications.pdf>

Version: 2024-02-01

80
papers

2,531
citations

218381

26
h-index

223531

46
g-index

80
all docs

80
docs citations

80
times ranked

4024
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. <i>Annals of Oncology</i> , 2017, 28, 1036-1041.	0.6	207
2	Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2011, 72, 73-77.	0.9	126
3	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 342-349.	0.8	120
4	Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. <i>Journal of Neuro-Oncology</i> , 2017, 135, 129-139.	1.4	116
5	Phase II Study of Asparagine-Glycine-Arginine- α -Human Tumor Necrosis Factor β , a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2604-2611.	0.8	111
6	Neutrophils in Gliomas. <i>Frontiers in Immunology</i> , 2017, 8, 1349.	2.2	101
7	Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin. <i>Clinical Cancer Research</i> , 2011, 17, 2581-2590.	3.2	94
8	Advances in the biology of malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , 2011, 37, 543-558.	3.4	94
9	Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey. <i>Lung Cancer</i> , 2012, 75, 360-367.	0.9	89
10	Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1155-1164.	3.3	76
11	A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. <i>British Journal of Cancer</i> , 2013, 108, 21-24.	2.9	69
12	Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. <i>Neuro-Oncology</i> , 2021, 23, 812-826.	0.6	60
13	Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. <i>Cancer</i> , 2010, 116, 4686-4695.	2.0	59
14	Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. <i>Cancer</i> , 2021, 127, 1620-1629.	2.0	56
15	Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2014, 84, 265-270.	0.9	52
16	Role of myeloid cells in the immunosuppressive microenvironment in gliomas. <i>Immunobiology</i> , 2020, 225, 151853.	0.8	50
17	Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 159-168.	1.2	49
18	Checkpoint inhibitors as treatment for malignant gliomas: α long way to the top. <i>Cancer Treatment Reviews</i> , 2018, 69, 121-131.	3.4	46

#	ARTICLE	IF	CITATIONS
19	Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. <i>Radiotherapy and Oncology</i> , 2014, 112, 425-429.	0.3	42
20	Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. <i>Cancers</i> , 2020, 12, 2283.	1.7	41
21	Reproducibility of the WHO classification of thymomas: Practical implications. <i>Lung Cancer</i> , 2013, 79, 236-241.	0.9	37
22	Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome. <i>Journal of Neurosurgery</i> , 2020, 132, 1692-1705.	0.9	35
23	Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. <i>Immunotherapy</i> , 2016, 8, 1363-1369.	1.0	34
24	Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. <i>Annals of Oncology</i> , 2016, 27, 1782-1787.	0.6	32
25	Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. <i>British Journal of Cancer</i> , 2014, 111, 220-226.	2.9	31
26	NKG2A expression identifies a subset of human V α 2 T α cells exerting the highest antitumor effector functions. <i>Cell Reports</i> , 2021, 37, 109871.	2.9	30
27	Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 3040-3046.	0.7	29
28	Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis. <i>European Radiology</i> , 2021, 31, 4079-4086.	2.3	27
29	First-In-Human Phase I Study of a Next-Generation, Oral, TGF β 2 Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6666-6676.	3.2	27
30	Correlation of microvascular fractal dimension with positron emission tomography [^{11}C]-methionine uptake in glioblastoma multiforme: Preliminary findings. <i>Microvascular Research</i> , 2010, 80, 267-273.	1.1	26
31	Imaging biomarkers in primary brain tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 597-612.	3.3	23
32	High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem-Cell Transplantation for the Treatment of Solid Tumors in Adults: A Critical Review. <i>Current Stem Cell Research and Therapy</i> , 2007, 2, 65-82.	0.6	22
33	Prognostic and predictive role of [^{18}F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. <i>Cancer Medicine</i> , 2017, 6, 2287-2296.	1.3	22
34	Expression of the Transcription Factor HEY1 in Glioblastoma: A Preliminary Clinical Study. <i>Tumori</i> , 2010, 96, 97-102.	0.6	21
35	Intensified chemotherapy with stem-cell rescue in germ-cell tumors. <i>Annals of Oncology</i> , 2012, 23, 815-822.	0.6	21
36	Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. <i>BMC Cancer</i> , 2015, 15, 486.	1.1	21

#	ARTICLE	IF	CITATIONS
37	Depatuzumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). <i>Cancers</i> , 2021, 13, 2773.	1.7	21
38	Future developments in the management of malignant pleural mesothelioma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 453-467.	1.1	20
39	Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. <i>Journal of Neuro-Oncology</i> , 2017, 131, 377-384.	1.4	20
40	Phase I and pharmacodynamic study of high-dose NGRhTNF in patients with refractory solid tumours. <i>British Journal of Cancer</i> , 2013, 108, 58-63.	2.9	19
41	Thymoma Associated with Myasthenia and Autonomic anti-Hu Paraneoplastic Neuropathy. <i>Tumori</i> , 2009, 95, 243-247.	0.6	18
42	Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment. <i>Acta Neurochirurgica</i> , 2018, 160, 1779-1787.	0.9	18
43	Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1367.	1.0	18
44	Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. <i>Future Oncology</i> , 2013, 9, 153-165.	1.1	17
45	Infertility risk and teratogenicity of molecularly targeted anticancer therapy: A challenging issue. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 1-13.	2.0	17
46	Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients' management: Close to the clinic?. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102879.	2.0	17
47	Treatment of patients with glioma during the COVID-19 pandemic: what we learned and what we take home for the future. <i>Neurosurgical Focus</i> , 2020, 49, E10.	1.0	17
48	Herpes Infections in Breast Cancer Patients Treated with Adjuvant Chemotherapy. <i>Oncology</i> , 2006, 71, 164-167.	0.9	16
49	Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 7527-7527.	0.8	16
50	Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. <i>Oncotarget</i> , 2017, 8, 67696-67708.	0.8	16
51	Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. <i>Radiotherapy and Oncology</i> , 2018, 127, 108-113.	0.3	15
52	Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study. <i>Journal of Clinical Oncology</i> , 2012, 30, 4117-4117.	0.8	14
53	Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6716.	1.8	13
54	Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study. <i>Radiotherapy and Oncology</i> , 2022, 167, 89-96.	0.3	13

#	ARTICLE	IF	CITATIONS
55	Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. <i>European Journal of Cancer</i> , 2013, 49, 989-998.	1.3	12
56	Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient. <i>Medicine (United States)</i> , 2019, 98, e18089.	0.4	11
57	Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors. <i>World Neurosurgery</i> , 2019, 126, e270-e280.	0.7	10
58	COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report. , 2021, 9, e001870.		10
59	Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations. <i>Cancers</i> , 2022, 14, 1125.	1.7	10
60	Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, e529-e531.	0.8	9
61	Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 503-521.	1.0	8
62	Role of ¹¹ C Methionine Positron Emission Tomography (¹¹ C METPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2313.	1.0	7
63	Neuro-Oncology During the COVID-19 Outbreak: A Hopeful Perspective at the End of the Italian Crisis. <i>Frontiers in Medicine</i> , 2020, 7, 594610.	1.2	7
64	Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study. <i>Cancers</i> , 2022, 14, 2425.	1.7	7
65	Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports. <i>Future Oncology</i> , 2015, 11, 1223-1232.	1.1	6
66	Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series. <i>Journal of Neurosurgery</i> , 2020, 135, 64-77.	0.9	5
67	Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 166, 170-177.	0.9	4
68	COVID-19 and liver cancer clinical trials: Not everything is lost. <i>Liver International</i> , 2020, 40, 1541-1544.	1.9	3
69	Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care. <i>Frontiers in Oncology</i> , 2020, 10, 926.	1.3	3
70	Interleukin-8 neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti-PD-(L)1-experienced patients with advanced cancer: initial phase 1 results. , 2020, , .		3
71	Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. <i>Tumori</i> , 2012, 98, 67e-71e.	0.6	3
72	Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGF β 2 inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2524-2524.	0.8	3

#	ARTICLE	IF	CITATIONS
73	The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing. <i>Radiotherapy and Oncology</i> , 2021, 156, 49-55.	0.3	2
74	Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients (PTS) with mismatch repair deficiency (MMRd): An observational study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2043-2043.	0.8	2
75	An Overview of Intracranial Ependymomas in Adults. <i>Cancers</i> , 2021, 13, 6128.	1.7	2
76	Treatment of malignant pleural mesothelioma: current status and future directions. <i>Clinical Investigation</i> , 2011, 1, 999-1018.	0.0	1
77	Immunotherapeutic early-phase clinical trials and malignant gliomas: a single-center experience and comprehensive immunophenotyping of circulating leukocytes. <i>Neuro-Oncology Advances</i> , 2021, 3, vtab160.	0.4	1
78	Quality of life of adult cancer survivors enrolled in Humanitas Research Hospital's survivorship care model. <i>Supportive Care in Cancer</i> , 2022, 30, 5561-5564.	1.0	1
79	Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007, 81, 323-325.	1.4	0
80	High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13512-e13512.	0.8	0